SHI (69) identified VIM-AS1 as a key LncRNA regulator; VIM-AS1 overexpression reduced the sensitivity to enzalutamide treatment, which plays a regulatory role in prostate cancer proliferation as well as enzalutamide sensitivity through the VIM-AS1/IGF2BP2/HMGCS1 axis. This evidence concerns the gene VIM-AS1 and prostate cancer.